Navigation Links
Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights
Date:3/3/2011

2010 is a $0.5 million grant Anadys was awarded under the U.S. government's Qualifying Therapeutic Discovery Project program.  The remaining decrease was primarily attributable to a $0.5 million decrease in ANA598 development costs and a $0.4 million decrease in ANA773 development costs.General and administrative expenses were $1.7 million for the fourth quarter of 2010, compared to $1.6 million for the fourth quarter of 2009.  The general and administrative expenses were relatively consistent for the fourth quarter of 2010 when compared to the fourth quarter of 2009.

Anadys' net loss was $2.4 million for the fourth quarter of 2010, compared to a net loss of $4.3 million for the fourth quarter of 2009.  Included in the net loss for the fourth quarter of 2010 is a $2.0 million gain resulting from a decrease in the Company's common stock warrant liability from September 30, 2010 to December 31, 2010.  The liability is associated with warrants that were issued in connection with our "registered direct" offering in June 2009.  Basic and diluted net loss per common share was $0.04 in the fourth quarter of 2010, compared to $0.11 in the fourth quarter of 2009.  

For the twelve months ended December 31, 2010, Anadys reported a net loss of $16.3 million, compared to $27.3 million for the twelve months ended December 31, 2009.  Basic and diluted net loss per common share was $0.38 and $0.81 for the twelve months ended December 31, 2010 and 2009, respectively.

2010 Data Presentations

  • AASLD 2010, Oral Presentation – results through 12 weeks from a Phase IIa study of ANA598 were reported.  ANA598 added to SOC accelerated the rate of viral clearance, with comparable response at ANA598 doses of 200 mg bid and 400 mg bid.  ANA598 also showed an excellent resistance profile and safety profile through 12 weeks of dosing in the study, with reported adverse events being typical for patients
    '/>"/>

  • SOURCE Anadys Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Anadys Pharmaceuticals Augments Management Team and Board of Directors
    2. Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference
    3. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2009 Financial Results
    4. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
    5. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
    6. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
    7. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
    8. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
    9. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
    10. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
    11. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/25/2014)... 25, 2014 Lawrence Livermore scientists Charles ... Reuters list of " The World's Most Influential Scientific ... the 3,000 researchers who were identified by analyzing citation ... who published the highest-impact work (2002-2012 and 2012-2013). The ... combustion modeling . , "This recognition is a ...
    (Date:7/25/2014)... July 25, 2014 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will ... June 30, 2014, after market close on Thursday, August 14, ... to the market opening on Friday, August 15, 2014, at ... China Standard Time) to review the Company,s financial results and ...
    (Date:7/24/2014)... , July 24, 2014  Now available is ... home. Rehealth Regenerative Therapies , located in ... other physically active people a new health option: ... Regardless of age, countless patients suffer from joint and ... such as muscle tears, torn rotator cuff, tennis elbow, ...
    (Date:7/24/2014)... A research team led by group leader Yung-Eun ... technology to synthesize sulfur-doped and nitrogen-doped graphenes which ... secondary batteries and fuel cells. Yung-Eun Sung is ... Nanoparticle Research at Institute for Basic Science* (IBS) ... , This achievement has great significance with regards ...
    Breaking Biology Technology:Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
    ... Researcher Appreciation Event ... ... PHOENIX, Oct. 3 ThirdBiotech Inc., http://www.thirdbiotech.com, a biotechnology incubator ... Appreciation Event to be held on Thursday, October 23rd, 2008,between noon and ...
    ... http://www.amdl.com ),AMDL, Inc. (Amex: ADL ), a leading ... the US, today announced that the,Company will present at ... on Tuesday, October 7, 2008 at 10:30 a.m. ET. ... York Hotel in the Morosco Room., The Maxim ...
    ... Support R&D Efforts and Clinical Trials Advancing,the ... Oct. 3 Micromet, Inc. (Nasdaq:,MITI) ("Micromet" ... proprietary antibodies for the treatment of cancer, ... has closed its previously,announced $40 million private ...
    Cached Biology Technology:First Annual Arizona Biotech Day Announced for October 23rd 2008 2First Annual Arizona Biotech Day Announced for October 23rd 2008 3AMDL, Inc. to Present at Maxim Group Growth Conference October 7, 2008 2AMDL, Inc. to Present at Maxim Group Growth Conference October 7, 2008 3Micromet Closes $40 Million Private Equity Placement 2Micromet Closes $40 Million Private Equity Placement 3Micromet Closes $40 Million Private Equity Placement 4
    (Date:7/25/2014)... is a complex congenital central nervous system disease ... the neural tubes during the embryonic phase. Many ... fecal incontinence and neurocognitive retardation. Such problems decrease ... life. Researchers at Ankara Physical Medicine and Rehabilitation ... performance in children with SB, using the Pediatric ...
    (Date:7/25/2014)... girls reach puberty is influenced by ,imprinted genes,a subset of ... gene. This is the first evidence that imprinted genes ... of this study were published today in the journal ... menarche, is a marker for the timing of puberty in ... varies between girls, is an inherited trait, and is linked ...
    (Date:7/25/2014)... a molecular testing panel developed at UPMC greatly ... surgery for patients with thyroid nodules and cancer, ... Institute (UPCI), partner with UPMC CancerCenter., The test, ... other diagnostic testing agencies, improved the chances of ... percent, according to the study published this month ...
    Breaking Biology News(10 mins):Could age of first period influence development of diseases in older women? 2Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3
    ... European College of Neuropsychopharmacology (ECNP) is pleased to ... 2009 ECNP Neuropsychopharmacology Award in Basic Science Research ... into the neurochemical basis of substance addiction. ... in the field of neuropsychopharmacology and its closely ...
    ... Researchers have made significant advances in the treatment of metastatic ... treat successfully once it has started to spread according ... congress, ECCO 15 ESMO 34 [1], in Berlin on ... seen rapid and dramatic shrinking of metastatic tumours in patients ...
    ... research team at the National Institute of Standards and ... possible cancer therapy has uncovered a delicate balancing act ... says they should be. Just like individuals in a ... because they get close together, but not too close. ...
    Cached Biology News:Trial of new treatment for advanced melanoma shows rapid shrinking of tumors 2Trial of new treatment for advanced melanoma shows rapid shrinking of tumors 3Therapeutic nanoparticles give new meaning to sugar-coating medicine 2
    ... 75 x ... recommended for immunohistochemistry of paraffin-embedded sections, ... at one end, markings ... normal procedures, precleaned, ...
    1000X solution used for inducing CopyControl™ based vectors to high copy numbers...
    Donor feline serum and plasma...
    Request Info...
    Biology Products: